• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.移植受者接种两剂严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗后的抗体反应不佳。
Clin Infect Dis. 2022 Mar 23;74(6):1093-1096. doi: 10.1093/cid/ciab580.
2
Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.体液和细胞免疫应答在 Sars-CoV-2 BNT162b2 疫苗接种的实体器官移植受者和健康对照者中的作用。
Transpl Infect Dis. 2022 Feb;24(1):e13772. doi: 10.1111/tid.13772. Epub 2021 Dec 21.
3
Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.接受两剂 BNT162b2 疫苗 6 个月后，实体器官移植受者和健康对照者的抗体浓度下降。
Front Immunol. 2022 Feb 23;13:832501. doi: 10.3389/fimmu.2022.832501. eCollection 2022.
4
Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者中灭活 SARS-CoV-2 疫苗和 BNT162b2 mRNA 疫苗的抗体反应差异。
Exp Clin Transplant. 2021 Dec;19(12):1334-1340. doi: 10.6002/ect.2021.0402.
5
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。
Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.
6
Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.在一组多样化的实体器官移植候选人和受者中，两剂严重急性呼吸综合征冠状病毒 2 疫苗的早期体液免疫反应。
Clin Transplant. 2022 May;36(5):e14600. doi: 10.1111/ctr.14600. Epub 2022 Feb 2.
7
Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab.在接受低剂量利妥昔单抗治疗的肾移植受者中，两剂 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Int J Urol. 2022 Nov;29(11):1279-1286. doi: 10.1111/iju.14978. Epub 2022 Jul 21.
8
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.肾移植受者对 SARS-CoV-2 mRNA 疫苗的抗体反应：一项前瞻性队列研究。
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4. doi: 10.1016/j.cmi.2021.04.028. Epub 2021 May 3.
9
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
10
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.CoronaVac 加强针接种后对 SARS-CoV-2 抗体反应的动力学。
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.

引用本文的文献

1
Comparison of Post-Vaccination Response (Humoral and Cellular) to BNT162b2 in Clinical Cases, Kidney and Pancreas Transplant Recipient with Immunocompetent Subjects over Almost Two Years of Parallel Monitoring.在近两年的平行监测中，对临床病例、肾和胰腺移植受者以及免疫功能正常的受试者接种BNT162b2后的反应（体液和细胞反应）进行比较。
Vaccines (Basel). 2024 Jul 26;12(8):844. doi: 10.3390/vaccines12080844.
2
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.评估奥密克戎亚变体主导期肾移植受者 COVID-19 重症的抗病毒治疗效果及相关危险因素：一项回顾性研究。
BMC Nephrol. 2024 Apr 8;25(1):124. doi: 10.1186/s12882-024-03561-7.
3
Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.新型冠状病毒肺炎疫苗在慢性肝病和肝移植患者中的血清学转换及安全性：一项系统评价。
Qatar Med J. 2023 Dec 12;2023(3):21. doi: 10.5339/qmj.2023.21. eCollection 2023.
4
Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis.影响肝移植受者 SARS-CoV-2 疫苗免疫原性和安全性的因素：系统评价和荟萃分析。
Front Immunol. 2023 Sep 5;14:1145081. doi: 10.3389/fimmu.2023.1145081. eCollection 2023.
5
Impact and management of COVID-19 in liver transplant candidates and recipients.新型冠状病毒肺炎对肝移植候选者及受者的影响与管理
Ann Gastroenterol. 2023 Sep-Oct;36(5):477-489. doi: 10.20524/aog.2023.0815. Epub 2023 Jul 3.
6
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.实体器官移植受者对 SARS-CoV-2 感染的易感性和对 COVID-19 疫苗接种的免疫反应。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S34-S45. doi: 10.1093/infdis/jiad152.
7
Humoral and Cellular Immunity following Five Doses of COVID-19 Vaccines in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.实体器官移植受者接种五剂新冠疫苗后的体液免疫和细胞免疫：一项系统评价和荟萃分析
Vaccines (Basel). 2023 Jun 27;11(7):1166. doi: 10.3390/vaccines11071166.
8
Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.实体器官移植受者接种第四剂严重急性呼吸综合征冠状病毒2疫苗后的血清学反应：一项系统评价和荟萃分析
Vaccines (Basel). 2023 Jun 21;11(7):1130. doi: 10.3390/vaccines11071130.
9
The Cellular and Humoral Immune Response to SARS-CoV-2 Messenger RNA Vaccines Is Significantly Better in Liver Transplant Patients Compared with Kidney Transplant Patients.与肾移植患者相比，肝移植患者对严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的细胞免疫和体液免疫反应明显更好。
Pathogens. 2023 Jul 5;12(7):910. doi: 10.3390/pathogens12070910.
10
Effects of Sirolimus Treatment on Fetal Hemoglobin Production and Response to SARS-CoV-2 Vaccination: A Case Report Study.西罗莫司治疗对胎儿血红蛋白生成及对SARS-CoV-2疫苗接种反应的影响：一项病例报告研究
Hematol Rep. 2023 Jul 12;15(3):432-439. doi: 10.3390/hematolrep15030044.

移植受者接种两剂严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗后的抗体反应不佳。

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.

机构信息

Sorbonne Université, Unité Médicale de Transplantation Hépatique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France.

出版信息

Clin Infect Dis. 2022 Mar 23;74(6):1093-1096. doi: 10.1093/cid/ciab580.

DOI:10.1093/cid/ciab580
PMID:34166499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8384412/
Abstract

A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.

摘要

在 133 名未感染过 2019 年冠状病毒病（COVID-19）的实体器官移植受者中，第二剂 BNT162b2 疫苗接种后 28 天，观察到的抗刺突抗体低应答率为 28.6%。未记录到严重不良事件。在两剂疫苗之间或之后报告了 4 例严重 COVID-19 病例。我们的数据提示需要改变疫苗策略。